 |
|
Incomplete Financial Disclosure in a Study of Cell-Free Hemoglobin-Based Blood Substitutes and Risks of Myocardial Infarction and Death
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: I would like to report an incomplete financial disclosure resulting from my oversight in not including my involvement in a US Government Provisional Patent Application in the Financial Disclosures in the meta-analysis on cell-free hemoglobin-based blood substitutes (HBBSs) and risks of myocardial infarction and death.1
In the Financial Disclosures section of the article, I reported that I had been paid $10 000 by Hemosol Inc to review a cardiac surgery trial of its HBBS product and that I had served as an unpaid special government consultant to the Food and Drug Administration on the HBBS product Hemopure (made by Biopure Corp, Cambridge, Massachusetts). However, I failed to disclose that my name is listed with Dr Mark T. Gladwin and other National Institutes of Health investigators on a US Provisional Application relating to hemoglobin-based oxygen carriers (HBOCs) that was filed in August of 2007. The Provisional Application relates to . . . [Full Text of this Article]
Charles Natanson, MD
cnatanson@cc.nih.gov
Critical Care Medicine Department
Clinical Center
National Institutes of Health
Bethesda, Maryland
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Resolving Unreported Conflicts of Interest
DeAngelis and Fontanarosa
JAMA 2009;302:198-199.
FULL TEXT
|
